Bicycle Therapeutics reports FY2022 net loss of $112.7M; cash $339.2M, runway into 2025

BICYCLE THERAPEUTICS PLC

2022-FY EPS reported -$3.80 revenue$14,463,000

Net loss of $30.0M in Q4 2022 ($1.01/share) and $112.7M for FY2022 ($3.80/share), vs $18.0M and $66.8M in prior year.
Cash and equivalents $339.2M at Dec 31, 2022, down from $438.7M; expected to fund operations into 2025.
R&D expenses rose to $81.6M in FY2022 from $44.9M, driven by clinical programs for BT5528, BT8009, and TICA platform.
BT8009 granted FDA Fast Track Designation for urothelial cancer; Phase II expansion initiated with RP2Ds established.
BT5528 continues in dose expansion; BT7480 in dose escalation; pipeline updates expected later in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BICYCLE THERAPEUTICS PLC reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss was $30.0 million, or $(1.01) basic and diluted net loss per share, for the three months ended December 31, 202, EPS $(1.01) basic and diluted net loss per share.

Period: the fourth quarter and full year ended December 31, 2022
Net income: Net loss was $30.0 million, or $(1.01) basic and diluted net loss per share, for the three months ended December 31, 202
EPS: $(1.01) basic and diluted net loss per share
Result: reported results

Exact text from the filing

On February 28, 2023, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter and the year ended December 31, 2022 and other business highlights.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BICYCLE THERAPEUTICS PLC filing history →

Source: SEC EDGAR

accession 0001104659-23-026349

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.